Carasent

Report Publication Announcement • Oct 26, 2023

Interim report Q3 2023

26 October2023

Disclaimer

Certain statements made in this Presentation may include forward-looking statements. These statements relate to the Company's expectations, beliefs, intentions or strategies regarding the future. The forward-looking statements reflect the Company's current views and assumptions with respect to future events and are subject to risks and uncertainties.

All though the Company believes that its expectations and the Presentation are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in the Presentation.

Carasent ASA is making no representations or warranty, expressed or implied, as to the accuracy, reliability or completeness of the Presentation, and neither Carasent ASA, nor any of its directors, officers, employees or advisors will have any liability to you or any other person resulting from your use.

Q3 Highlights

Q3 2023 Summary

Revenue growth of 17% YoY

3

Distribution of NOK 250 million through share buyback and cash

Organic growth of 7% YoY

28 clinics signed for Webdoc in Sweden

Share buyback completed in Q3

5

Business and market update

Cost savings continues to improve profitability

• Adj. EBITDA margin
• Adj. EBITDAC margin¹
• Revenue

Focus now

▪ Sales

• In general focus on increasing sales through improving established products and new sales and marketing strategies
• Our new nimble organization will allow us to speed up in Norway
• No focus on consultancy revenue nor selling licenses
• Grow into our costs
• Additional savings by the end of the year
• Focus on COGS and keeping staff costs steady
• Launch Webdoc X
• Establishing first market and entry strategy
• Meeting potential customers and setting up pilots
• More about this at CMD 7/11

Financial Review

Q3 2023 Financial summary

Recurring revenue growth at 13% –slow quarter for consulting revenues

• Sticky revenue base with recurring revenues around 95% in Q3
• Currency effect of NOK (2.5m) compared to Q2 2023
• Slow quarter for consulting revenues
• Transaction based recurring revenues are slower in summer month, relatively stable organic growth in recurring revenues YoY

Organic recurring revenue growth of 13% in Q3 YoY

Cash cost reduction of NOK 15 million compared to Q1 2023

Cash cost base development 2023 Comments

• Cash cost NOK 15 million lower in Q2 compared to Q1
• Decrease partly driven by holiday effects and currency
• Cost savings with estimated savings of ~40m per year

Profitability and cash flow starting to improve